894 related articles for article (PubMed ID: 15671528)
1. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells.
Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T
Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528
[TBL] [Abstract][Full Text] [Related]
2. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
3. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
4. [Allogeneic dendritic cell vaccine pulsed with heat shocked tumor cell lysate can enhance antitumor immunity].
You J; Wang CL; Hao XS
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(39):2785-90. PubMed ID: 18167273
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells.
Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y
Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056
[TBL] [Abstract][Full Text] [Related]
6. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells.
Koido S; Hara E; Homma S; Torii A; Toyama Y; Kawahara H; Watanabe M; Yanaga K; Fujise K; Tajiri H; Gong J; Toda G
Clin Cancer Res; 2005 Nov; 11(21):7891-900. PubMed ID: 16278414
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.
Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S
Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060
[TBL] [Abstract][Full Text] [Related]
8. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.
Feili-Hariri M; Falkner DH; Morel PA
J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574
[TBL] [Abstract][Full Text] [Related]
9. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
10. Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination.
Tan C; Dannull J; Nair SK; Ding E; Tyler DS; Pruitt SK; Lee WT
J Surg Res; 2013 Dec; 185(2):904-11. PubMed ID: 23891424
[TBL] [Abstract][Full Text] [Related]
11. [Induction of Th1 immune response against tumor by genetically engineered fusion of tumor cells and dendritic cells].
Zhang W; Yang H; Zeng H; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):61-4. PubMed ID: 12015071
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic effects of treatment of pancreatic carcinoma by interleukin-23 and apoptotic cell antigen-modified dendritic cell vaccine: experiment with mice].
Tan G; Wang ZY; Yin S
Zhonghua Yi Xue Za Zhi; 2006 Apr; 86(14):943-6. PubMed ID: 16759530
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor immunity derived from a novel vaccine of fusion hybrid between dendritic and engineered myeloma cells.
Hao S; Bi X; Xu S; Wei Y; Wu X; Guo X; Carlsen S; Xiang J
Exp Oncol; 2004 Dec; 26(4):300-6. PubMed ID: 15627063
[TBL] [Abstract][Full Text] [Related]
15. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
17. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity.
Xia D; Li F; Xiang J
Cancer Biother Radiopharm; 2004 Jun; 19(3):322-30. PubMed ID: 15285878
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates.
Ju DW; Tao Q; Lou G; Bai M; He L; Yang Y; Cao X
Cancer Res; 2001 May; 61(9):3735-40. PubMed ID: 11325846
[TBL] [Abstract][Full Text] [Related]
19. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity.
Saha A; Chatterjee SK; Foon KA; Primus FJ; Bhattacharya-Chatterjee M
Cancer Res; 2003 Jun; 63(11):2844-54. PubMed ID: 12782590
[TBL] [Abstract][Full Text] [Related]
20. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
